2023 World Conference on Lung Cancer (Posters)-EP11.03. Incidence of Cardiotoxicity in Patients Treated for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors

EP11.03. Incidence of Cardiotoxicity in Patients Treated for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to assess the incidence and type of cardiotoxicity in patients with non-small cell lung cancer (NSCLC) who were treated with immune checkpoint inhibitors (ICPi). ICPi, including PD-1 inhibitors, PD-L1 inhibitors, and CTLA-4 inhibitors, have improved patient outcomes but are known to have immune-related adverse events (irAE). Cardiovascular adverse events (CVAEs), including myocarditis, are rare but can be fatal. The study analyzed data from 134 patients who received at least one dose of ICPi for NSCLC between 2019 and 2021. The primary outcome was to determine the incidence of ICPi-related cardiotoxicities, and the secondary outcomes included identifying trends in monitoring practices, risk factors, and management. <br /><br />The results showed that 68 patients (50.7%) experienced a CVAE, with the most common being QTc prolongation, arrhythmias, and thromboembolisms. Among the Black patients, 70% experienced a CVAE, compared to 50% of Asian patients and Non-Hispanic White patients. Four deaths were attributed to cardiac arrest. Among current or former smokers without cardiovascular co-morbidities, 26.3% experienced a CVAE, while 56.5% of non-smokers with CV co-morbidities had a CVAE. Additionally, out of 109 patients with at least one baseline cardiovascular comorbidity, only 70 (64.2%) had a recommended baseline electrocardiogram.<br /><br />The study highlights the need for stronger monitoring guidelines for ICPi-related CVAEs and increased awareness of their potential in NSCLC patients. The high rate of QTc prolongation observed may be influenced by concurrent use of QTc prolonging agents. The incidence of QTc prolongation may be underestimated due to the lack of baseline electrocardiograms for many patients. Overall, the study emphasizes the importance of screening, monitoring, and managing cardiotoxicity in patients treated with ICPi for NSCLC.

Asset Subtitle

Luis Raez

Meta Tag

Speaker Luis Raez

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

cardiotoxicity

non-small cell lung cancer

immune checkpoint inhibitors

QTc prolongation

arrhythmias

thromboembolisms

Black patients

cardiac arrest

smokers

baseline electrocardiogram